Global Research Syndicate
No Result
View All Result
  • Latest News
  • Consumer Research
  • Survey Research
  • Marketing Research
  • Industry Research
  • Data Collection
  • More
    • Data Analysis
    • Market Insights
  • Latest News
  • Consumer Research
  • Survey Research
  • Marketing Research
  • Industry Research
  • Data Collection
  • More
    • Data Analysis
    • Market Insights
No Result
View All Result
globalresearchsyndicate
No Result
View All Result
Home Data Collection

New Alzheimer’s research strengthens evidence for re-analyzing data in ‘failed’ clinical trials – UB Now: News and views for UB faculty and staff

globalresearchsyndicate by globalresearchsyndicate
August 20, 2020
in Data Collection
0
New Alzheimer’s research strengthens evidence for re-analyzing data in ‘failed’ clinical trials – UB Now: News and views for UB faculty and staff
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

READ ALSO

Chattanoogans favor Tim Kelly in mayoral poll

Logica Research Finds a Paradox in Money Management During COVID-19

New UB research on Alzheimer’s disease reveals strong evidence that clinical trials on drugs that appeared not to benefit patients with the disease should now be re-analyzed in light of discoveries about a human-specific gene that divides the population into a one-to-three ratio. 

The research builds on previous work by the UB group. That work found that this gene, CHRFAM7A, which is unique to humans but isn’t present in everyone in its active form, can determine whether or not patients will respond to three of the four Alzheimer’s treatments approved by the Food and Drug Administration that increase acetylcholine, a neurotransmitter involved in learning and memory.

That work illuminated why promising mice studies of potential Alzheimer’s drugs targeting the alpha 7 nicotinic receptor appeared to be unsuccessful when they advanced to human trials.

“This uniquely human gene modifies the alpha 7 nicotinic receptor, and as a consequence, drugs that are optimized in mice are insufficient for 75% of the population that has the active CHRFAM7A gene and the humanized receptor,” says Kinga Szigeti, corresponding author, director of UB’s Alzheimer’s Disease and Memory Disorders Center, professor of neurology in the Jacobs School of Medicine and Biomedical Sciences at UB, and part of UBMD Neurology.

“This underlying, previously unknown genetic heterogeneity, especially with this ratio, undermined drug development efforts,” Szigeti explains. “Our data indicate that drugs that target the nerve cells in which acetylcholine acts as a neurotransmitter, known as the cholinergic system, may benefit 25% of the individuals and now we can identify who they are.

“For Alzheimer’s, if we can treat 25% of patients, that is 1.5 million people,” she says. “That would be a major advance.”

The research was conducted on induced pluripotent stem cells converted from the skin cells of patients with Alzheimer’s disease and validated in clinical data from a 10-year, longitudinal, multicenter cohort study by the Texas Alzheimer Research and Care Consortium (TARCC) on 345 Alzheimer’s patients, as well as data from the UB cohort.  

The new research, published Aug. 18 in EBioMedicine, reports results from the iPSC model and the pharmacogenetic studies.

“This system that we created models the 25% of patients who could respond to the cholinergic drugs that supposedly failed in clinical trials, and contrasts them with the 75% whom likely will need a different approach,” Szigeti says. “This is the best evidence so far that those clinical trials should be re-analyzed.”

The research also provides evidence that individualizing treatment to patients’ genotypes will be key to attacking Alzheimer’s disease.

“This is the first proof of concept study that genotype and mechanism-specific treatment is feasible in AD,” the paper reports.

The researchers have concluded that instead of one disease for which a single drug is the solution, Alzheimer’s disease may, like cancer, represent a number of diseases, each of which will require its own targeted treatment. 

“It takes a simple blood test to determine a patient’s genotype, which will reveal whether or not a patient will respond to this class of drugs,” Szigeti says.

The results of the UB study would need to be validated in larger, double-blind clinical trials, she adds, noting that this can be achieved by re-analyzing the completed trials, saving millions of dollars.

UB co-authors, in addition to Szigeti, are Ivanna Ihnatovych, Barbara Birkaya, Ziquiang Chen, Aya Ouf, Dinesh Indurthi Venkata, Jonathan E. Bard, Julien Kann, Alexandrea Adams, Lee Chaves, Ralph H. Benedict, Anthony Auerbach and Gregory Wilding. Norbert Sule of Roswell Park Comprehensive Cancer Center is a collaborator.  

The research was supported by the Texas Alzheimer’s Research Consortium (TARCC) and funded by the state of Texas through the Texas Council on Alzheimer’s Disease and Related Disorders, the Alzheimer Association, the Edward A. and Stephanie E. Fial Fund and the Community Foundation for Greater Buffalo.

Related Posts

Chattanoogans favor Tim Kelly in mayoral poll
Data Collection

Chattanoogans favor Tim Kelly in mayoral poll

January 16, 2021
Logica Research Finds a Paradox in Money Management During COVID-19
Data Collection

Logica Research Finds a Paradox in Money Management During COVID-19

January 16, 2021
Policy directive on GPS issued in closing days of Trump administration
Data Collection

Policy directive on GPS issued in closing days of Trump administration

January 16, 2021
Some area residents hesitant over COVID-19 vaccine
Data Collection

Some area residents hesitant over COVID-19 vaccine

January 16, 2021
CU Boulder researchers see little change to single-cell organism
Data Collection

CU Boulder researchers see little change to single-cell organism

January 16, 2021
Hyde Park Art Center Hosts Free Virtual MLK Day Celebration | The Crusader Newspaper Group – The Chicago Cusader
Data Collection

Hyde Park Art Center Hosts Free Virtual MLK Day Celebration | The Crusader Newspaper Group – The Chicago Cusader

January 16, 2021
Next Post
Global Air Bubble Bags Market Scope and Price Analysis of Top Manufacturers Profiles 2019-2025 – Instant Tech Market News

Spin Desalting Columns Market Swot Analysis By Key Players Thermo Fisher Scientific, Bio-Rad Laboratories, GE Healthcare, Ciro Manufacturing

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

POPULAR NEWS

‘Vatican Blackout’ Trends on Twitter as Trigger-Happy Users Try to Link It with US Election Fraud

‘Vatican Blackout’ Trends on Twitter as Trigger-Happy Users Try to Link It with US Election Fraud

January 10, 2021
Global Food Authenticity Industry

Fifth Third Bank Partners with Cardtronics to Enhance Brand Visibility in Carolinas through ATM Branding Program

February 4, 2020
Horowitz: Asian-American researcher fired from Michigan State administration for advancing facts about police shootings

Horowitz: Asian-American researcher fired from Michigan State administration for advancing facts about police shootings

July 8, 2020
Digital Learning Market 2020 industry report explores segmented by growth opportunities, emerging-trends, and industry verticals till 2025

Online Brand Protection Software Market report reviews size, share, analysis, trends, growth and forecast 2025

March 6, 2020
Survey finds 40% of fashion brands have not paid suppliers | Apparel Industry News

Survey finds 40% of fashion brands have not paid suppliers | Apparel Industry News

May 29, 2020

EDITOR'S PICK

Bears attack 1.0600 to revisit two-month-old support area

Bears attack 1.0600 to revisit two-month-old support area

July 7, 2020
Industrial Control Transformer Market Entry Strategies, Countermeasures, Economic Impact and Leading Marketing Channels to 2028 – BIZNEWS

Industrial Control Transformer Market Entry Strategies, Countermeasures, Economic Impact and Leading Marketing Channels to 2028 – BIZNEWS

December 18, 2020
Online Survey Software Market New Era Of Industry & Forecast 2017-2025 – Fusion Science Academy

Non-opioid Analgesic Patch Market Research Reports Analysis by 2026 – Melanian News

January 31, 2020
Healthcare Cloud Computing Market by Product, Deployment, Component, Pricing, Service – Analysis & Global Forecasts to 2025 – ResearchAndMarkets.com

Healthcare Cloud Computing Market by Product, Deployment, Component, Pricing, Service – Analysis & Global Forecasts to 2025 – ResearchAndMarkets.com

October 12, 2020

Categories

  • Consumer Research
  • Data Analysis
  • Data Collection
  • Industry Research
  • Latest News
  • Market Insights
  • Marketing Research
  • Survey Research
  • Uncategorized

Recent Posts

  • Chattanoogans favor Tim Kelly in mayoral poll
  • Spiders in space are so unhappy they can’t even build decent webs
  • Orphan Drugs Market –Development Strategies of Manufacturers with SWOT Analysis, Business Growing Status and Future Forecast 2021-2024
  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

Copyright © 2020 Globalresearchsyndicate.com.

No Result
View All Result
  • Latest News
  • Consumer Research
  • Survey Research
  • Marketing Research
  • Industry Research
  • Data Collection
  • More
    • Data Analysis
    • Market Insights

Copyright © 2020 Globalresearchsyndicate.com.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In